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Abstract Sarcopenia, the age-related skeletal muscle de-
cline, is associated with relevant clinical and socioeconomic
negative outcomes in older persons. The study of this phe-
nomenon and the development of preventive/therapeutic
strategies represent public health priorities. The present
document reports the results of a recent meeting of the
International Working Group on Sarcopenia (a task force
consisting of geriatricians and scientists from academia and
industry) held on June 7–8, 2011 in Toulouse (France). The
meeting was specifically focused at gaining knowledge on
the currently available biomarkers (functional, biological, or
imaging-related) that could be utilized in clinical trials of
sarcopenia and considered the most reliable and promising
to evaluate age-related modifications of skeletal muscle. Spe-
cific recommendations about the assessment of aging skeletal
muscle in older people and the optimal methodological design
of studies on sarcopenia were also discussed and finalized.
Although the study of skeletal muscle decline is still in a very
preliminary phase, the potential great benefits derived from a
better understanding and treatment of this condition should
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encourage research on sarcopenia. However, the reasonable
uncertainties (derived from exploring a novel field and the
exponential acceleration of scientific progress) require the adop-
tion of a cautious and comprehensive approach to the subject.
1 Introduction
One of the most recognized changes in body composition
with senescence is the loss of skeletal muscle mass. This
loss occurs even among physically active older persons, and
it was originally termed “sarcopenia” for the Greek words
“flesh” and “loss” [1]. The age-related loss in skeletal mus-
cle mass is associated with substantial social and economic
costs and is characterized by impairments in strength, limita-
tions in function, and ultimately physical disability and insti-
tutionalization [2–4]. In consideration of the increased
awareness of this syndrome and the continued rapid develop-
ment of therapeutic strategies to slow or reverse sarcopenia,
the InternationalWorkingGroup on Sarcopenia was convened
to address issues related to the successful conduct of clinical
trials in this area [5]. This task force, consisting of geriatricians
and scientists from academia and industry, met again in Tou-
louse, France in June of 2011 to discuss the current state of the
art in the development of biomarkers to be utilized in clinical
trials on sarcopenia. The purpose of this meeting was to gain
an understanding of the currently available parameters that
could be utilized in clinical trials of sarcopenia and to discuss
future research needs in this area. Specific topics that were
addressed include: review of current consensus definitions of
sarcopenia, the importance of muscle performance and qual-
ity, biomarkers in other clinical states and chronic diseases,
potential biomarkers for sarcopenia, applications in clinical
trials, and recommendations for future studies.
2 Definition of sarcopenia
Since the advent of the term “sarcopenia” in 1989, there has
been a dramatic increase in publications in this area and
clinical interest in this condition [6]. Originally described as
the age-related decrease in skeletal muscle mass [7], until
very recently, there has been a lack of consensus on the
operational definition of sarcopenia without clinically ap-
propriate correlates for this syndrome. In the past 2 years, a
number of academic societies have put forward operational
definitions of sarcopenia [8–11]. Although each consensus
definition has some distinct features, there is general agree-
ment among these groups on the definition of sarcopenia. A
summary of consensus sarcopenia definitions is presented in
Table 1. The characteristics of sarcopenia highlighted in
these reports include an objective measure of muscle or fat
free mass using dual energy X-ray absorptiometry (DXA) or
computed tomography (CT), a reliable measure of muscle
strength, and/or an objective test of physical functioning.
Although the sequence of events and specific recommenda-
tions somewhat differ, the general approaches proposed
require that patients be identified with measured deficits in
physical function for which sarcopenia may be the cause
and subsequently quantification of muscle strength and
mass to definitively confirm the diagnosis.
3 Definition of a biomarker
A biomarker is defined as “a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention” [12]. Hence, biomarkers
support the diagnosis, facilitate the tracking of changes
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Table 1 Summary of consensus sarcopenia definitions
Group IANA Sarcopenia Task Force [8] European Working Group on Sarcopenia in
Older People [10]
Special Interest Group: cachexia–anorexia in
chronic wasting diseases [11]
Sarcopenia with limited mobility [9]
Target
popula-
tion
Subjects with clinical declines in
physical function, strength, or
health status
All persons aged 65 years and older Older persons Persons older than 60 years with clinical declines
in physical function, strength, or health status.
Exclude specific muscle diseases, peripheral
vascular disease with intermittent claudicatio,
central and peripheral nervous system disorders,
and cachexia
Screening Physical function (4-m gait speed).
If gait speed <1.0 m/s, proceed to
body composition evaluation
Gait speed. If gait speed ≤0.8 m/s, proceed to
body composition evaluation. If gait speed
>0.8 m/s, measure hand grip strength; if low
muscle strength, proceed to body
composition evaluation
Distance walked during a 6-min walk test (cut-
point: 400 m) or gait speed <1.0 m/s (4- to 6-m
track length)
Operative
definition
Poor functioning plus low ratio
between appendicular lean mass
(assessed by DXA) and squared
height (≤7.23 kg/m2 in men, ≤5.67
kg/m2 in women)
Low muscle mass in patients with gait speed
≤0.8 m/s or normal gait speed but low
muscle strength
Low muscle mass (≥2 standard deviations below
the mean measured in young adults of the same
sex and ethnic background) plus low usual gait
speed (<0.8 m/s in the 4-m walking test). Gait
speed test can be replaced by other physical
performance measures.
Poor functioning plus low appendicular lean mass
(≥2 standard deviations below the mean
measured in healthy persons aged 20–30 years
old from the same ethnic group)
J
C
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M
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in muscle strength [21]. It is also noteworthy that pharmaco-
logic interventions that increase muscle mass/size do not
necessarily improve voluntary strength. Similarly, physical
activity interventions that increase muscle strength do not
necessarily augment muscle size [22, 23]. Noticeably, gains
in muscle strength secondary to increased physical activity
generally precede measurable changes in skeletal muscle
mass/size.
The progressive muscle atrophy with aging is associated
with a loss of overall muscle force and changes in force and
power generation of the remaining muscle fibers [24]. Howev-
er, several additional physiological mechanisms that accompa-
ny the phenomenon of sarcopenia may directly influence
muscle function and force production with advancing age.
Recent evidence has shown that adipose tissue accumulation
around and between muscle fibers concomitant with reductions
in muscle cross-sectional area occurs with aging, and that this
skeletal muscle attenuation is inversely associated with muscle
performance [18, 25]. Age-related changes in the nervous
system may also play a substantial role in the decline in muscle
power generation [26]. These include loss of motor neurons
and concomitant remodeling of motor units through collateral
reinnervation [27], impairment of neuromuscular activation
observed as decreased maximal motor unit firing rates
[28–30], and uncoordinated patterns of intermuscular neural
activation [31]. Finally, changes in individual muscle fiber
composition and intrinsic contractile properties may influence
the decline in muscle force among older adults. For instance,
cross-sectional observations suggest that reductions in muscle
torque may be related to changes in fiber composition and, in
particular, to the preferential atrophy of type II (fast-twitch)
fibers with aging [32]. Specific changes in the intrinsic ability
of aged muscle to generate force have also been observed [33].
Decreases in specific force (force normalized per cross section-
al area) and unloaded shortening velocity in type I and IIA
fibers have been reported in older males compared with young
controls [32, 34]. Conversely, recent longitudinal data have
demonstrated that, despite reductions in whole muscle cross-
sectional area, single muscle fiber contractile function is pre-
served with advancing age as existing fibers may compensate
and partially correct these deficits, therefore maintaining opti-
mal force-generating capacity [14].
Although precise and valid measures of muscle mass are
important components of sarcopenia assessment, these gross
measures of muscle size do not adequately account for the
dynamic components (force, power, activation) of muscle func-
tion that are responsible for performing activities of daily
living. Future trials on sarcopenia adopting clinically meaning-
ful endpoints should evaluate these key biomarkers of muscle
function through the use of state-of-the-art methodologies.
5 Quantitative assessment of sarcopenia
The bidimensional definition of sarcopenia simultaneously
includes a functional parameter (i.e., muscle performance)
and a quantitative index (i.e., muscle mass). Therefore,
techniques aimed at capturing the objective amount of skel-
etal muscle mass are required. Multiple methodologies are
currently available to accomplish this task [35].
DXA is the most commonly used imaging technique
for several reasons: first of all, because it is commonly
available in clinical and research settings, being relatively
inexpensive, sufficiently precise, and well-accepted by
older persons. Second, the initial operative definition of
sarcopenia proposed by Baumgartner and colleagues [3]
was based on appendicular lean mass measured by DXA.
Later on, DXA was used to provide alternative definitions
of sarcopenia based on the fat-adjusted residual method
Table 2 Possible biomarkers to be used in trials on sarcopenia
Inclusion–
exclusion
criteria
Baseline
evaluation
End-point
assessment
Muscle function
Physical performance
measures
+++ +++ +++
Muscle strength measures +++ +++ +++
Disability +++ +++ +++
Muscle mass
Anthropometry + - -
Bioelectrical impedance
analysis
+ + +
Dual energy X-ray absorp-
tiometry
+++ ++ ++
Computerized tomography ++ +++ +++
Magnetic resonance
imaging
++ +++ +++
Echography ++ ++ ++
Electrical impedance
myography
+ ++ ++
Mechanisms, biological confoundersa
Inflammation ++ ++ ++
Oxidative damage ++ ++ ++
Antioxidants ++ ++ ++
Apoptosis + ++ ++
Nutritional parameters
(albumin, hemoglobin,
urinary creatinine, etc.)
+++ ++ ++
Hormones
(dehydroepiandrosterone,
testosterone, insulin-like
growth factor-1, etc.)
++ ++ ++
- not recommended for this use; + may be of use, but severely limited;
++ suitable for this use; +++ recommended for this use
a The importance of all of these biomarkers in the evaluation of sarco-
penia will largely depend on the study hypotheses, the specific aims,
and/or the target population
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[36]. Nevertheless, it cannot be ignored that the first
operative definition is dated more than 10 years, and during
this time, several steps forward have been made in refining
imaging techniques as well as understanding the sarcopenia
phenomenon.
The identification of the “gold standard” for the quanti-
tative evaluation of muscle mass in clinical trials (which is
currently lacking) should be based on criteria of accuracy
(i.e., the degree of conformity of a measure to a standard or a
true value), precision (i.e., the degree of refinement with
which an operation is performed or a measurement stated),
reproducibility (i.e., the quality of being reproducible under
the same operating conditions over a period of time or by
different operators), sensitivity to change (i.e., the degree of
being modified by interventions), and accessibility (i.e., its
usual availability in research and clinical centers).
DXA currently represents the more accessible technique for
body composition assessment. It may accurately provide esti-
mates of lean, fat, and bone tissues in the entire body or in
specific regions. Moreover, it is inexpensive and quick to be
performed. The radiation exposure associated with DXA is low
and highly acceptable (about 1 mrem, a quantity similar to that
of a 3-day background). The main limitations of this imaging
approach reside in some analytical differences across manufac-
turers and models, and the risk of biased results due to the low
differentiation between water and bone-free lean tissue.
CT accurately measures a direct physical property of the
muscle (e.g., cross-sectional area and volume). It also allows
the evaluation of muscle density (a parameter related to
intramyocellular lipid deposits) as well as subcutaneous
and intramuscular adipose tissue deposition. The radiation
exposure associated with this technique is higher (i.e., about
15 mrem) than with DXA.
Magnetic resonance imaging (MRI) presents a high agree-
ment with CT and provides similar measures. It does not
involve radiation exposure and also has the additional capac-
ity of multiple slice acquisition, thus rendering 3D volumetric
estimates. The lack of radiation exposure makes MRI the
method of choice for many studies where ethics committee
or national authority approval is more difficult to obtain for
CT. The major limitations of this methodology reside in the
higher technical complexity and costs, and in the inapplica-
bility to subjects with older models of implantedmetal devices
(e.g., joint prostheses, pace-makers, etc.). Both CT and MRI
may be limited in the ability to accommodate very obese
individuals.
Finally, it needs to be emphasized that imaging provides
information only about one of the two sarcopenia dimensions.
As discussed earlier, changes in muscle function and quantity
do not necessarily follow similar trajectories with aging [37].
Therefore, interventions able to increase lean mass may not
necessarily produce parallel gains in strength and vice versa
[38]. To overcome this issue and include the two components
of sarcopenia in the same variable, it has been proposed to
compute an index of skeletal muscle quality derived from the
ratio between strength and mass [15, 39, 40].
One of the most recently developed techniques which might
find larger application in the near future for the evaluation of
sarcopenia is the electrical impedance myography (EIM) [41].
This is a noninvasive, painless approach based on the surface
application and measurement of a high-frequency, low-
intensity electrical current applied to specific muscles. EIM
detects changes in the conductivity and permittivity of skeletal
muscle caused by alterations in muscle composition and struc-
ture. EIM is repeatable and sensitive to skeletal muscle changes
in patients with amyotrophic lateral sclerosis [42].Moreover, its
changes over time may also have clinical relevance as they are
predictive of survival in animal models of amyotrophic lateral
sclerosis [43]. Finally, it is also noteworthy that the EIM phase
shows a consistent inverse relationship with age [44].
An alternative method to measure skeletal muscle size is
by ultrasonography. This technique has shown to be a valid
(versus MRI-based measurements) and highly reliable way
for assessing cross-sectional areas of large individual human
muscles [45]. It is particularly useful in mobility-impaired
subjects who cannot easily be transported to scanners such
as CT or MRI machines.
Also remarkable is the development of mass isotopomer
distribution analysis based on the evaluation of protein and
proteome synthesis rate obtained by heavy water labeling
[46, 47]. Although this technique can still be considered
suitable mainly for research settings, its flexibility and the
large amount of information it provides about a wide spec-
trum of proteins make it extremely promising.
Other techniques are also available to detect sarcopenia,
but their limited validation, low accuracy, and difficult large-
scale implementation discourage their use. For example, bio-
electrical impedance analysis (BIA) is a popular, very simple,
and low-cost technique, but its results are far from being
accurate. The BIA technique is based on the notion that tissues
rich in water and electrolytes are less resistant to the electrical
passage than adipose tissue. The BIA is therefore based on a
single body resistance parameter (not a direct measure of
skeletal muscle), and its results can be easily altered by fluid
retention and health status in general. For these reasons, a
recent consensus paper by the Society of Sarcopenia, Cachex-
ia and Wasting Disorders has discouraged the use of BIA for
the assessment of sarcopenia [9].
6 Definition of critical thresholds
There is still resistance to accept sarcopenia as a clinical
condition despite its well-established relationship with major
health-related negative events (in particular, mobility and
physical disability) [8]. This issue might (at least partly) be
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explained by the current lack of clinically relevant thresholds
that distinguish normal from abnormal values of skeletal
muscle mass.
Several approaches can be adopted to identify critical
cut-points. A paradigmatic example potentially lending
support to the operative definition of sarcopenia might be
provided by the approach previously adopted to identify
osteoporosis on the basis of bone mineral density. In
fact, approaches that have been developed for bone and
osteoporosis may serve well for skeletal muscle and
sarcopenia. The clinical definition of a specific condition
(which will consequently lead to the indication for treat-
ment) might be based on:
1. A parallel clinical diagnosis. For osteoporosis, diagnosis
can be obtained by evaluating the presence of vertebral
fractures or deformities at the X-ray examination. Verte-
bral fractures indicate decreased bone strength, regardless
of bone mineral density. It is well established that patients
with vertebral fractures present an increased risk of new
events and therefore require treatment. This approach is
legitimate and may well work, but may find some limi-
tations when applied in primary prevention.
2. A biological assessment. Given its well-established as-
sociation with fracture risk, bone mineral density may
represent the key parameter on which to rely to deter-
mine the presence or absence of osteoporosis. However,
bone mineral density (like any other biological marker)
exists as a continuous variable, does not present a clear
threshold, and is parallel to gradients of risk. Although
necessary to provide clinical relevance to biological
markers, any categorization will lead to a loss of infor-
mation and will inevitably introduce an “arbitrary” de-
cision. For the definition of osteoporosis, the cut-off
defining the disease was arbitrarily set by a committee
which judged the -2.5 standard deviations at the T-score
as an adequate match between risk and prevalence. One
major problem with the bone definition that should not
be repeated for sarcopenia is the inclusion of osteope-
nia. Osteopenia (defined by a bone mineral density T-
score ranging between -1 and 2.5) encompasses about
50 % of the female healthy population and has led to
confusion and concerns among policy-makers regarding
the validity of a construct that cannot really be consid-
ered abnormal. An approach consistent with this model
has also been adopted in the definition of other clinical
conditions such as anemia [48].
3. The risk of adverse clinical outcomes. The indication to
treatment of a specific condition (e.g., osteoporosis)
might be based on the evaluation of risk of events
(i.e., fractures) resulting from the assessment of multiple
factors (which may even not include bone mineral den-
sity) [49]. This approach will not be exclusively based
on the single evaluation of a (potentially inaccurate and/
or arguable) biomarker, but on a more comprehensive
screening and on cost-effectiveness analyses (e.g., treat
if the 10-year risk is exceeding a critical threshold).
With this rationale, the FRAX [50] and QFractureScores
[51] algorithms were recently developed to guide osteo-
porosis treatment.
In summary, the presence of sarcopenia might be deter-
mined by (1) relying on a clinical diagnosis closely related
to skeletal muscle decline (e.g., mobility disability) after
exclusion of secondary causes, (2) a representative scientific
committee identifying a critical threshold for a biological
parameter directly representative of skeletal muscle health,
and/or (3) developing a risk index to guide treatment.
7 Biological markers of sarcopenia
Given the syndromic nature of sarcopenia, intervention
strategies aimed at preventing/treating its process might
need to target multiple risk factors. In this context, several
biological markers have been shown to be associated with
skeletal muscle mass, strength, and function, thus represent-
ing potential markers for the effect of the studied interven-
tions. Such a list is quite long, and each biomarker identifies
a specific mechanism contributing the age-related skeletal
muscle decline, although they are not specific to muscle and
many are likely to turn out to be only weakly associated
with clinically relevant outcomes. The most common
markers are inflammatory biomarkers [e.g., C-reactive pro-
tein [52, 53], interleukin-6 [52–54], and tumor necrosis
factor-α [52, 54]], clinical parameters [e.g., hemoglobin
[55, 56], serum albumin [57, 58], and urinary creatinine
[59]], hormones [e.g., dehydroepiandrosterone sulfate [60],
testosterone [61], insulin-like growth factor-1 [62], and vi-
tamin D [63–65]], products of oxidative damage [e.g., ad-
vanced glycation end-products [66], protein carbonyls [67,
68], and oxidized low-density lipoproteins [69]], or antiox-
idants [e.g., carotenoids [70, 71] and α-tocopherol [70]].
Other promising biomarkers have been identified in the
last years and may represent useful parameters to more
directly explore sarcopenia because they are closely related
to skeletal muscle changes. For example, plasma concen-
trations of procollagen type III N-terminal peptide (P3NP)
represent an interesting marker of skeletal muscle remod-
eling [72, 73]. P3NP is a fragment released by the cleav-
age of procollagen type III to generate collagen III (a
protein produced in soft connective tissues, skin, and
muscle). Preliminary studies have also suggested an in-
teresting role played by biomarkers specifically linked to
the neuromuscular junction in evaluating skeletal muscle
modifications [74, 75].
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8 Clinical outcome measures of sarcopenia
Ultimately, the goal of clinical trials for sarcopenia treat-
ments will require the evaluation of clinical benefit. In fact,
clinical measures can also be considered as biomarkers as
they reflect the impact of the pathological process of sarco-
penia on the patient's health. The assessment of measures of
muscle strength (e.g., hand grip), muscle power (e.g., leg
extension power), and physical performance [e.g., Short
Physical Performance Battery [4] and gait speed tests] com-
prise important indices of the individual's physical function.
In addition, functional outcome measures will need to be
developed in order to help understand the impact of any
treatment-related quantitative gains in performance on the
person's daily life.
9 Recommendations
9.1 Adoption of comprehensive operative definitions
The lack of a unique operative definition of sarcopenia and
the numerous methodological issues could potentially hin-
der efforts to study sarcopenia and to develop effective
treatments. Such difficulties should not hamper the process
of exploring this syndrome which severely affects the health
status of millions of older persons. The current ambiguities
can be easily overcome by adopting flexible and compre-
hensive approaches in the design of studies, for example, by
avoiding reliance on a single parameter or technique to
evaluate age-related skeletal muscle decline. The adoption
of a variety of assessment approaches in combination is
agreeable. Although this might lead to the risk of conflicting
results (and increase the need of resources), it will serve to
(1) capture different domains of the sarcopenia syndrome,
(2) provide useful insights about the pathophysiological
process underlying this phenomenon, and (3) facilitate the
development and use of the findings in future and more
definitive studies. In this context, it is noteworthy the lack
of studies simultaneously testing different techniques mea-
suring skeletal muscle (e.g., MRI, CT, DXA, etc.) in rela-
tionship with clinically meaningful outcomes. Such studies
might greatly help in the standardization of instruments and
in the adoption of an univocal direction in the study of
sarcopenia.
9.2 MRI and CT scan to be equally considered as “gold
standard” imaging techniques
It is now clear that, to be adequately assessed, the sarcopenia
phenomenon cannot merely rely on the evaluation of the
contractile part of skeletal muscle. The close relationship
between lean mass and adipose tissue in determining age-
related decline of skeletal muscle is evident [38, 76, 77].
Therefore, techniques allowing the simultaneous evaluation
of fat and muscle should be preferred. DXA, CT, and MRI
are the most important assessment instruments. CT and MRI
should be considered the “gold standard” techniques. The
balance of pros and cons for both CT and MRI does not
allow a clear indication on which of the two should be
preferred. Resources, instrument availability, and need of
details will represent the factors guiding the investigator's
preference for one over the other. On the other hand, DXA
should not be discarded and still represents the instrument
more likely to promote the “clinical relevance” of sarcope-
nia. For its characteristics, DXA may be an extremely inter-
esting methodology to be used for preliminary screening.
Moreover, its use in combination with either CT or MRI will
help drive the research in the field towards more clinical
aspects. While imaging and other biomarkers will be valu-
able tools for initial proof of concept studies, assessment
tools for evaluating the effect of treatments on outcomes
reflecting clinical benefit will be required to support eventual
pivotal studies.
9.3 Adequate length of study
To evaluate the efficacy of a specific intervention on sarco-
penia, it is necessary that the follow-up will be sufficiently
long to allow the hypothesized modifications of biomarkers.
Surely, not all biomarkers will be similarly influenced by the
intervention. Such variations will depend on multiple fac-
tors, including the population characteristics, the type and
strength of the tested intervention, and the sensibility of the
biomarker to changes. However, 6 months have been gen-
erally indicated as the minimum timeframe to expect
changes in imaging parameters.
9.4 Sarcopenia is a “work in progress”
The study of sarcopenia is still in its infancy, but we have
clearly acknowledged the great potential benefits arising
from the understanding and treatment of this condition at
both person and population levels. Taking together the
uncertainties of exploring a novel field with the exponential
acceleration of scientific progress, it is currently difficult to
provide long-lasting statements, recommendations, and
guidelines. It is likely that what seems reasonable today will
be confounded by several studies in the near future. For this
reason, extreme caution is needed to avoid jeopardizing the
future development of research in the field. It is important to
consider the study of sarcopenia as a “work in progress,”
always amenable to changes and redirections. After all,
the first phase II trials in this syndrome are just starting,
and this is the appropriate time to raise doubts and pose
questions. With time, a stronger foundation for sarcopenia
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research will be developed, which will ultimately lead to
larger scale and more definitive studies. In this context, it
is critical that an ongoing dialogue be initiated and sustained
among investigators with an interest in age-dependent decline
of muscle.
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